Endpoints News· Ayisha Sharma·· 23 小时前AI 评分27
#ESMO26：SystImmune/BMS 与恒瑞医药披露 EGFR 突变肺癌数据
#ESMO26: SystImmune/BMS and Hengrui detail data in EGFR-mutant lung cancer
正文 · 原文
MADRID — Several drugmakers with antibody-drug conjugates are jockeying for a spot in EGFR-mutant non-small cell lung cancer patients who progress after AstraZeneca’s Tagrisso. And it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源：Endpoints News · endpoints.news